

Assoc. Prof. SERKAN AKIN

Personal Information

Office Phone: [+90 312 305 2965](tel:+903123052965)

Email: serkan.akin@hacettepe.edu.tr

Web: <https://avesis.hacettepe.edu.tr/serkan.akin>

International Researcher IDs

ORCID: 0000-0002-7542-9229

Yoksis Researcher ID: 201536

Education Information

Post Doctorate of Medicine, Hacettepe University, Turkey 2013 - 2016

Expertise In Medicine, Hacettepe University, Turkey 2007 - 2011

Undergraduate, Istanbul Bilim University, School Of Medicine, Turkey 1999 - 2006

Foreign Languages

English, C1 Advanced

Research Areas

Oncology

Academic Titles / Tasks

Associate Professor, Hacettepe University, Kanser Enstitüsü, Klinik Onkolojisi A.B.D., 2018 - Continues

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **The Role of Radiotherapy in Indolent Ocular Adnexal and Orbital Lymphomas**
YAZICI G., AKIN S., KAHVECİOĞLU A., YİĞİT E., TÜRKER F. A., YILDIZ F.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2024 (SCI-Expanded)
- II. **Comprehensive analysis of orbital lymphoma in a Turkish cohort: clinical characteristics, histological subtypes, treatment modalities, prognostic factors, and implications for management**
AKYILDIZ A., Ismayilov R., Rustamova N., Tokatli M., KOÇ İ., AKIN S., KIRATLI H., BARIŞTA İ.
Annals of Hematology, vol.103, no.3, pp.905-915, 2024 (SCI-Expanded)
- III. **Factors Influencing Immunotherapy Outcomes in Cancer: Sarcopenia and Systemic Inflammation**
Ucgu E., Guven D. C., Ucgu A. N., ÖZBAY Y., ONUR M. R., AKIN S.
CANCER CONTROL, vol.31, 2024 (SCI-Expanded)
- IV. **SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research**

GÜVEN D. C., Sahin T. K., AKIN S., Uckun F. M.

ONCOLOGIST, vol.27, no.11, 2022 (SCI-Expanded)

- V. **Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination**
GÜVEN D. C., Sahin T. K., AKIN S., Uckun F. M.
ONCOLOGIST, vol.27, 2022 (SCI-Expanded)
- VI. **Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement**
Akin S., Hosing C., Khouri I., Ahmed S., Alousi A., Fowler N., Joseph J., Truxillo J., Ramdial J. L., Maadani F., et al.
BLOOD ADVANCES, vol.6, no.7, pp.2267-2274, 2022 (SCI-Expanded)
- VII. **Comparison of clinical and PET-derived prognostic factors in patients with non-Hodgkin lymphoma: a special emphasis on bone marrow involvement**
Kupik O., Akin S., Tuncel M., Eren G., Türker A., Kars A., Erbaş B.
NUCLEAR MEDICINE COMMUNICATIONS, vol.41, no.6, pp.540-549, 2020 (SCI-Expanded)
- VIII. **Gemcitabine, Oxaliplatin and Paclitaxel (GemPOx) in Patients with Relapsed or Refractory Germ Cell Tumors After High Dose Chemotherapy, A Retrospective Single-Center Experience**
Acar R., Erturk I., Kiziloz H., Okcelik S., Yildiz B., Aykan M. B., Keskin G. S. Y., Buyukturan G., AKIN S., Karadurmus N.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.30, no.4, pp.191-196, 2020 (SCI-Expanded)
- IX. **Efficacy of Pazopanib in patients with metastatic uterine sarcoma: A multi-institutional study**
Sunar V., Korkmaz V., AKIN S., GÜVEN D. C., ARIK Z., Ates O., Yilmaz M., Meydanli M. M., Oksuzoglu B.
JOURNAL OF BUON, vol.24, no.6, pp.2327-2332, 2019 (SCI-Expanded)
- X. **Association between androgen receptor status and prognosis in triple negative breast cancer**
Sunar V., Dogan H. T., Sarici F., ATEŞ Ö., AKIN S., BAŞPINAR B., AKSOY S., Altundag K.
JOURNAL OF BUON, vol.23, no.5, pp.1325-1330, 2018 (SCI-Expanded)
- XI. **Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcoma**
AKIN S., DİZDAR Ö., KARAKAS Y., Turker A., Kars A.
CURRENT PROBLEMS IN CANCER, vol.42, no.3, pp.344-349, 2018 (SCI-Expanded)
- XII. **Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms**
AKIN S., DİZDAR Ö., Hayran M.
ANNALS OF SURGICAL ONCOLOGY, vol.24, 2017 (SCI-Expanded)
- XIII. **Evaluation of complementary and alternative medicine trials registered in clinicaltrials.gov database**
DİZDAR Ö., BİLGİN E., AKIN S., KILIÇKAP S., HAYRAN M.
JOURNAL OF BUON, vol.22, no.2, pp.530-534, 2017 (SCI-Expanded)
- XIV. **Prediction of central lymph node metastasis in patients with thyroid papillary microcarcinoma**
Akin S., Aksoy D. Y., AKIN S., KILIÇ M., Yetisir F., BAYRAKTAR M.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.47, no.6, pp.1723-1727, 2017 (SCI-Expanded)
- XV. **Left laterality is an independent prognostic factor for metastasis in N3 stage breast cancer**
Karatas F., Sahin S., Erdem G. U., ATEŞ Ö., BABACAN T., AKIN S., SEVER A. R., Ozisik Y., Altundag K.
JOURNAL OF BUON, vol.21, no.4, pp.851-858, 2016 (SCI-Expanded)
- XVI. **Trastuzumab 1-year vs 9-week in early-stage HER2-positive, lymph node negative breast cancer patients**
Ozen M., Gunduz M., ATEŞ Ö., BABACAN T., SEVER A. R., AKIN S., Ozisik Y., Altundag K.
JOURNAL OF BUON, vol.21, no.4, pp.799-808, 2016 (SCI-Expanded)
- XVII. **Correlation of educational status and clinicopathological characteristics of breast cancer: a single center experience**
Sarici F., BABACAN T., Buyukhatipoglu H., Balakan O., SEVER A. R., KERTMEN N., Unlu O., ATEŞ Ö., DIKER O., AKIN S., et al.
JOURNAL OF BUON, vol.21, no.4, pp.826-831, 2016 (SCI-Expanded)
- XVIII. **Interpretation of survival data: which graphical analysis is appropriate?**
Dizdar O., AKIN S., HAYRAN M.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, vol.8, no.4, pp.312, 2016 (SCI-Expanded)

- XIX. **Analysis of the Adjuvant Hormone Therapy Randomized Trial**
Karakas Y., AKIN S., DİZDAR Ö., AKSOY S.
JOURNAL OF CLINICAL ONCOLOGY, vol.34, no.17, pp.2070-2071, 2016 (SCI-Expanded)
- XX. **Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer**
ATEŞ Ö., BABACAN T., KERTMEN N., Sarici F., Cenoli A., AKIN S., Karakas Y., KILIÇKAP S., Ozisik Y., SEVER A. R., et al.
JOURNAL OF BUON, vol.21, no.2, pp.375-381, 2016 (SCI-Expanded)
- XXI. **Leg cramps associated with tamoxifen use - possible mechanism and treatment recommendations**
Karatas F., Sahin S., BABACAN T., AKIN S., SEVER A. R., Altundag K.
JOURNAL OF BUON, vol.21, no.2, pp.520, 2016 (SCI-Expanded)
- XXII. **Vaccination Attitudes Among Patients with Cancer Receiving Chemotherapy**
AKIN S., DİZDAR Ö., ÖZİŞİK L., TANRIOVER M., KAMISLI S., ERMAN M., HAYRAN M.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.26, no.3, pp.167-172, 2016 (SCI-Expanded)
- XXIII. **Insomnia caused by aromatase inhibitors; a therapeutic challenge in patients with breast cancer**
Karatas F., Sahin S., BABACAN T., AKIN S., SEVER A. R., Altundag K.
JOURNAL OF BUON, vol.20, no.6, pp.1640, 2015 (SCI-Expanded)
- XXIV. **Does eribulin mesylate cause recurrent transient diplopia?**
Karatas F., Hacıoğlu B., AKIN S., BABACAN T., SEVER A. R., Altundag K.
JOURNAL OF BUON, vol.20, no.5, pp.1379, 2015 (SCI-Expanded)
- XXV. **Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer**
BABACAN T., Efe O., Hasirci A. S., Demirci F., Buyukhatipoglu H., Balakan O., Sarici F., KERTMEN N., Esin E., AKIN S., et al.
TUMORI J, vol.101, no.4, pp.418-423, 2015 (SCI-Expanded)
- XXVI. **Can aromatase inhibitors cause forgetfulness in women with breast cancer ?**
Karatas F., AKIN S., BABACAN T., SEVER A. R., Altundag K.
JOURNAL OF BUON, vol.20, no.3, pp.935, 2015 (SCI-Expanded)
- XXVII. **Chemotherapy might not be beneficial in lymph node-negative, hormone-positive, and HER2-negative breast cancer patients: a long-term retrospective analysis**
BABACAN T., Buyukhatipoglu H., Balakan O., KERTMEN N., Suner A., Sarici F., AKIN S., ATEŞ Ö., Karakas Y., Aslan A., et al.
JOURNAL OF BUON, vol.20, no.2, pp.479-486, 2015 (SCI-Expanded)
- XXVIII. **Acquired C1 esterase inhibitor deficiency in a marginal zone lymphoma patient treated with rituximab**
ATEŞ Ö., Sunar V., BABACAN T., AKIN S., KERTMEN N., Altundag K.
JOURNAL OF BUON, vol.20, no.1, pp.349, 2015 (SCI-Expanded)
- XXIX. **Which sequence best protects the heart against trastuzumab and anthracycline toxicity An electron microscopy study in rats**
KERTMEN N., AKSOY S., ÜNER A., ÖZGÜR Ö., keskin o., babacan t, furkan s., arık z., akın S.
Anticancer Research, 2015 (SCI-Expanded)
- XXX. **Clinical implications of intratumoral heterogeneity ofHER2gene amplification in locally advanced HER2-positive breast cancer patients**
Hacıoğlu B., AKIN S., SEVER A. R., Altundag K.
FUTURE ONCOLOGY, vol.11, no.18, pp.2495-2497, 2015 (SCI-Expanded)
- XXXI. **How long should we maintain anti-HER2 therapy for metastatic breast cancer patients with complete remission?**
Hacıoğlu B., AKIN S., BABACAN T., SEVER A. R., Altundag K.
FUTURE ONCOLOGY, vol.11, no.20, pp.2799-2801, 2015 (SCI-Expanded)
- XXXII. **Comparison of three different induction regimens for nasopharyngeal cancer**
KERTMEN N., AKSOY S., CENGİZ M., YAZICI G., KESKİN O., Babacan T., Sarici F., AKIN S., Altundag K., Gullu H. I.
Asian Pacific Journal of Cancer Prevention, vol.16, no.1, pp.59-63, 2015 (SCI-Expanded)

- XXXIII. **Molecular subtypes in patients with inflammatory breast cancer; A single center experience**
KERTMEN N., BABACAN T., Keskin O., Solak M., Sarici F., AKIN S., ARIK Z., Aslan A., ATEŞ Ö., AKSOY S., et al.
JOURNAL OF BUON, vol.20, no.1, pp.35-39, 2015 (SCI-Expanded)
- XXXIV. **Acute erythroid leukemia in a patient with chronic lymphocytic leukemia**
GÜVEN D. C., BABACAN T., Sarici F., AKIN S., Altundag K., Turker A.
JOURNAL OF BUON, vol.19, no.4, pp.1127, 2014 (SCI-Expanded)
- XXXV. **Breast sarcoma: A rare malignancy**
Gul G., BABACAN T., AKIN S., Sarici F., Altundag K.
JOURNAL OF BUON, vol.19, no.2, pp.577, 2014 (SCI-Expanded)
- XXXVI. **A novel targeted therapy in breast cancer: Cyclin dependent kinase inhibitors**
AKIN S., BABACAN T., Sarici F., Altundag K.
JOURNAL OF BUON, vol.19, no.1, pp.42-46, 2014 (SCI-Expanded)
- XXXVII. **Nasopharyngeal sarcoidosis: a rare involvement**
Akin S., Akin S., KARADAĞ Ö., KALYONCU U., Balci S., ÖZGEN MOCAN B.
RHEUMATOLOGY INTERNATIONAL, vol.32, no.5, pp.1407-1409, 2012 (SCI-Expanded)
- XXXVIII. **Concomitant renal cell carcinoma and lymphoid malignancies: a case series of five patients and review of the literature**
Serefhanoglu S., BÜYÜKAŞIK Y., GÖKER H., Akin S. C., Akin S., SAYINALP N., HAZNEDAROĞLU İ. C., ÖZCEBE O. İ.
MEDICAL ONCOLOGY, vol.27, no.1, pp.55-58, 2010 (SCI-Expanded)

Articles Published in Other Journals

- I. **Bilateral Testicular Plasmacytoma Preceding Multiple Myeloma with Extramedullary Renal Involvement: A Case Report**
KAVGACI G., KÖKSAL B., ARIK Z., BARIŞTA İ., AKIN S.
PLASMATOLOGY, 2024 (ESCI)
- II. **Bilgisayarlı Tomografi, Pozitron Emisyon Tomografisi ve Nükleer Manyetik Rezonans Görüntülemeye Temel Kavram ve İlkeler.**
BAYARI S. H., AKIN S., TUNCEL M.
Bati Karadeniz Tıp Degisi, vol.7, no.3, pp.269-278, 2023 (Peer-Reviewed Journal)
- III. **Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: The Past and the Future**
Srour S. A., AKIN S.
Journal of Immunotherapy and Precision Oncology, vol.6, no.1, pp.19-30, 2023 (Scopus)
- IV. **A Novel Tumor Marker for Anaplastic Lymphoma Kinase (+) Lymphoma: Beta-Human Chorionic Gonadotropin**
Moral K., SEYHAN E., KUTLAY D. Y., AKIN S.
Journal of Oncological Science, vol.9, no.1, pp.46-49, 2023 (Scopus)
- V. **Bilateral primary breast lymphoma in a pregnant woman: a case report and literature review**
YILDIRIM H. Ç., AKYILDIZ A., Ismayilov R., Demirok N., BENLİ B. S., Guven D. C., AKIN S., YALÇIN Ş., BARIŞTA İ.
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, vol.15, no.4, pp.307-310, 2022 (ESCI)
- VI. **Farklı Trombositopeni Sebeplerinin Klinik ve Laboratuvar Bulguları**
AKIN S., AKIN Ş., Karaağaç A. T., HAZNEDAROĞLU İ. C.
Journal of Contemporary Medicine, vol.7, no.4, pp.316-322, 2017 (Peer-Reviewed Journal)
- VII. **Symptomatic Adrenal Insufficiency due to Bilateral Adrenal Non-Hodgkin's Lymphoma**
AKIN Ş., Akin S., TUNCEL M., ERSÖZ G. N.
Turkish Journal of Endocrinology and Metabolism, vol.20, pp.108-110, 2016 (Scopus)

Refereed Congress / Symposium Publications in Proceedings

- I. **The Role of FDG PET/CT Detecting Bone Marrow Involvement in Non-Hodgkin's Lymphoma Patients**
KUPIK O., Akin S., TUNCEL M., TÜRKER A., Kars A., Erbas B.
31st Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Düsseldorf, Germany, 13 - 17 October 2018, vol.45
- II. **Clinicopathologic characteristics of patients with recurrent or metastatic synovial sarcoma**
ATEŞ Ö., AKSOY S., YETER H. H., Akin S., KERTMEN N., DİZDAR Ö., TÜRKER F. A., KARS S. A.
2016 ASCO Annual Meeting, 29 May - 03 June 2016
- III. **The impact of the total size of lesions in multifocal multicentric breast cancer on survival**
Karakas Y., DİZDAR Ö., Akin S., ATEŞ Ö., ŞENDUR M. A. N., AKSOY S., GÜLLÜ İ. H., ÖZİŞİK Y. Y., ALTUNDAĞ M. K.
2016 ASCO Annual Meeting, 29 May - 03 June 2016
- IV. **The impact of the total size of lesions in multifocal/multicentric breast cancer on survival.**
Karakas Y., Dizdar O., Akin S., Ates O., Sendur M. A. N., Aksoy S., Hayran M., Gullu İ. H., Ozisik Y. Y., Altundag K.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, vol.34
- V. **Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer**
Ateş Ö., Babacan T., SARICI F., KERTMEN N., CENOLİ A., Akin S., KARAKAS Y., KILIÇKAP S., AKSOY S., ÖZİŞİK Y. Y., et al.
ASCO Annual Meeting, 29 May - 02 June 2015
- VI. **Signet ring cell carcinoma of breast: Single center experience.**
AKIN S., DIKER O., KERTMEN N., ATEŞ Ö., DİZDAR Ö., YALÇIN Ş., Altundag K.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- VII. **Correlation of educational status and clinicopathological characteristics of breast cancer: A single center experience.**
Diker O., Babacan T., Buyukhatipoglu H., Kertmen N., Balakan O., Sever A. R., Unlu O., Ates O., Sarici S. F., Akin S., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- VIII. **Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER-2 negative breast cancer.**
Altundag K., Babacan T., Efe O., Hasirci A. S., Demirci F., Buyukhatipoglu H., Balakan O., Sarici F. S., Kertmen N., Esin E., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- IX. **Which sequence prevents the heart from trastuzumab and anthracycline toxicity: Electron microscopy study in rats**
Aksoy S., Kertmen N., ÜNER A., Sargon M., Ozkayar O., Keskin O., Babacan T., Sarici S. F., Sendur M. A. N., Arik Z., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- X. **Comparison of three different induction regimen in nasopharyngeal cancer: CF versus DC versus DCF.**
Kertmen N., Aksoy S., Cengiz M., Yazici G., Keskin O., Babacan T., Sarici S. F., Akin S., Altundag K., Gullu I. H.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XI. **Is there any correlation between molecular subtypes and blood groups in breast cancer?**
Kucukoztas N., Oguz A., Babacan T., Dizdar O., Rahatli S., Sarici S. F., Keskin G. S. Y., Diker O., Akin S., Altundag O., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32

Metrics

Publication: 56

Citation (WoS): 104

Citation (Scopus): 92

H-Index (WoS): 6

H-Index (Scopus): 6

Non Academic Experience

RİZE EĞİTİM ARAŞTIRMA HASTANESİ

ANKARA ULUS DEVLET HASTANESİ

YUKARIŞEYHLER SAĞLIK OCAĞI ÇERMİK/ DİYARBAKIR

KOCAELİ ÜNİVERSİTESİ TIP FAKÜLTESİ TIBBİ PATOLOJİ ABD